We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Expanded Steroid Control Launched at the 2015 AACC Annual Meeting

By LabMedica International staff writers
Posted on 30 Jul 2015
Expanded Steroid Control has been launched that now contains nine analytes of interest at clinically relevant levels for mass spectrometry and separation science technology. More...


The nine analytes included in the specialty matrix are Corticosterone, Cortisol, Cortisone, Dehydroepiandrosterone (DHEA), Progesterone, 17α-Hydroxyprogesterone, Testosterone, with the addition of Androstenedione and 11 Deoxycortisol.

The Expanded Steroid Control is manufactured by UTAK (Valencia, CA, USA) within its proprietary SMx Serum Specialty Matrix. For use with any methodology, UTAK's stock and custom quality controls are handcrafted and sold to Clinical, Toxicology and Esoteric laboratories globally. UTAK's Expanded Steroid Control in SMx Serum, is offered in individual packs for Levels 1, 2, 3, 4 and a Negative Control. The International Organization for Standardization (ISO) accreditation guidelines note that independent third party quality controls should be used instead of, or in addition to, any control materials supplied by the reagent or instrument manufacturer. UTAK offers hundreds of stock and custom serum, whole blood, urine and oral fluids controls for use with any methodology, on any testing platform.

Jim Plutchak, CEO of UTAK, said, “Our goal is always to craft Quality Controls for Clinical and Esoteric laboratories that are as close to a human matrix as possible. Due to the issue of endogenous steroid levels in serum-based matrix products, we developed a Steroids Control in our SMx Specialty Matrix. The result is a third party control that esoteric laboratories can depend on for their laboratory developed tests.” Charles E. Pippenger, PhD, adjunct professor Department of Neurosciences, University of Vermont College of Medicine added, “Inter-laboratory comparison of results, made possible with a uniform control, allows labs to be confident that test results generated are accurate.”

The Expanded SMx Steroid Control was released at the 2015 American Association of Clinical Chemistry (AACC) Meeting & Clinical Lab Expo held July 26–30, in Atlanta (GA, USA).

Related Links:
UTAK
University of Vermont College of Medicine 
American Association of Clinical Chemistry



New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Gold Member
Aspiration System
VACUSAFE
New
Prefilled Tubes
Prefilled 5.0ml Tubes
New
Clinical Informatics Platform
CLARION™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Industry

view channel
Image: Pathlight combines WGS and dPCR to identify and longitudinally track large‑scale genomic changes, known as structural variants (photo courtesy of SAGA Diagnositcs)

Roche Affiliate Expands MRD Portfolio with SAGA Acquisition

Foundation Medicine, Inc., an independent affiliate of Roche, announced plans to expand its monitoring portfolio with SAGA Diagnostics’ Pathlight, a personalized, tumor-informed molecular residual disease... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.